NCT00043927已完成3 期
An Open-Label, Multicenter, Randomized, Phase III Study Comparing Oral Topotecan/Cisplatin Versus Etoposide/Cisplatin as Treatment for Chemotherapy-naive Patients With Extensive Disease-Small Cell Lung Cancer.
适应症
相关药物
试验速览
- 阶段
- 3 期
- 状态
- 已完成
- 入组人数
- 760
- 试验地点
- 177
- 主要终点
- Overall Survival
研究概览
简要总结
This study will gather and compare data about the effectiveness and safety of two different treatments for extensive Small Cell Lung Cancer (SCLC) in patients who have not received previous chemotherapy. One treatment will use an investigational drug in combination with an FDA approved chemotherapy. The other treatment will use a combination of two FDA approved chemotherapy drugs.
研究设计
- 研究类型
- Interventional
- 分配方式
- Randomized
- 干预模型
- Parallel
- 主要目的
- Treatment
- 盲法
- None
入排标准
- 年龄范围
- 18 Years 至 —（Adult, Older Adult）
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •Written informed consent (patient's written understanding of and agreement to participate in this study).
- •Patients with confirmed extensive small cell lung cancer (SCLC).
- •No prior chemotherapy within 5 years of the diagnosis of SCLC.
- •Presence of either measurable or non-measurable SCLC by X-ray or physical examination.
- •At least 3 weeks since last major surgery (a lesser period is acceptable if decided to be in the best interest of the patient).
- •At least 24 hours since prior radiotherapy. Patients who have received radiotherapy must have recovered from any reversible side effects, such as nausea and vomiting.
- •Laboratory criteria: Patients must have adequate bone marrow reserve and adequate kidney and liver function.
排除标准
- •Symptoms of spreading of the disease to the brain that requires treatment with drugs called steroids.
- •Any active infection.
- •Severe medical problems other than the diagnosis of SCLC, that would limit the ability of the patient to follow study guidelines or that would expose the patient to extreme risk.
- •Ongoing or planned chemotherapy, immunotherapy, radiotherapy, or investigational therapy for the treatment of SCLC.
- •Use of an investigational drug within 30 days before the first dose of study medication.
- •Women who are pregnant or lactating.
- •Patients of child-bearing potential who refuse to practice an adequate form of birth control.
- •Patients with clinical evidence of any stomach or intestinal (GI) condition.
- •Patients requiring treatment with the drug cyclosporin A.
结局指标
主要结局
Overall Survival
次要结局
- response rates, response duration, time to progression, tolerability and patient-perceived disease status and well being for patients
研究者
研究点 (177)
Loading locations...
相似试验
撤回
3 期
A Clinical Study to Compare the Efficacy and Safety of HLX10 in Combination With HLX04 Versus Sorafenib as the First-line Treatment in Patients With Locally Advanced or Metastatic HCCHepatocellular Carcinoma (HCC)NCT04465734Shanghai Henlius Biotech
终止
3 期
Study of Intravenous Ceftolozane/Tazobactam Compared to Piperacillin/Tazobactam in Ventilator-Associated PneumoniaVentilator-Associated Pneumonia (VAP)NCT01853982Cubist Pharmaceuticals LLC, a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA)4
已完成
3 期
Cyclophosphamide, Lenalidomide and Dexamethasone (CRD) Versus Melphalan (200 mg/m2) Followed By Autologous Stem Cell Transplant (ASCT) In Newly Diagnosed Multiple Myeloma SubjectsMultiple MyelomaNCT01091831Fondazione EMN Italy Onlus389
已完成
3 期
Simultaneous Versus Sequential Use of Adjuvant Chemotherapy and GnRHa in Treating ER+,Premenopausal Breast CancerBreast CancerNCT01712893Fudan University216
进行中（未招募）
3 期
Combined Apalutamide, Radiotherapy, and LHRH Agonist in Prostate Cancer Patients After ProstatectomyProstate CancerNCT04181203UNICANCER490